CHARLES J PARKER, M.D.
Osteopathic Medicine at Circle Of Hope Dr, Salt Lake City, UT
License number
Utah 173510-1205
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Utah 173510-1205
Category
Osteopathic Medicine
Type
Hematology
License number
Utah 173510-1205
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
1950 Circle Of Hope Dr, Salt Lake City, UT 84112
Phone
(801) 581-2121
(801) 213-3900
(801) 213-3900
Personal information
See more information about CHARLES J PARKER at radaris.comName
Address
Phone
5264 Arapaho Dr, Ogden, UT 84403
Professional information
Charles Edwin Parker, Salt Lake City UT
Specialties:
Internist
Address:
1950 Circle Of Hope Dr, Salt Lake City, UT 84112
Education:
University of North Carolina, School of Medicine - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine)
Operations Manager, Ipic At Northrop Grumman Aerospace Systems
Position:
Operations Manager, IPIC at Northrop Grumman Aerospace Systems
Location:
Greater Salt Lake City Area
Industry:
Defense & Space
Work:
Northrop Grumman Aerospace Systems
-
Operations Manager, IPIC
Charles J Parker, Salt Lake City UT
Specialties:
Internal Medicine, Hematology & Oncology, Hematology, Medical Oncology, Hematology
Work:
Uumc Hematology Dept
50 N Medical Dr, Salt Lake City, UT 84132 Huntsman Cancer Institute
2000 Circle Of Hope Dr, Salt Lake City, UT 84112 University Hospitals Medical Group Inc
1950 Circle Of Hope Dr, Salt Lake City, UT 84112 Va Medical Center
500 Foothill Dr, Salt Lake City, UT 84148
50 N Medical Dr, Salt Lake City, UT 84132 Huntsman Cancer Institute
2000 Circle Of Hope Dr, Salt Lake City, UT 84112 University Hospitals Medical Group Inc
1950 Circle Of Hope Dr, Salt Lake City, UT 84112 Va Medical Center
500 Foothill Dr, Salt Lake City, UT 84148
Education:
University of North Carolina (1975)
Real Estate Professional
Location:
Greater Salt Lake City Area
Industry:
Real Estate
Dr. Charles J Parker - MD (Doctor of Medicine)
Hospitals:
University Utah Hospital HEM
1950 Circle Of Hope Dr SUITE 2, Salt Lake City 84112
Huntsman Cancer Institute
2000 Circle Of Hope Dr SUITE 2E, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
University Utah Hospital HEM
1950 Circle Of Hope Dr SUITE 2, Salt Lake City 84112
Huntsman Cancer Institute
2000 Circle Of Hope Dr SUITE 2E, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
1950 Circle Of Hope Dr SUITE 2, Salt Lake City 84112
Huntsman Cancer Institute
2000 Circle Of Hope Dr SUITE 2E, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
University Utah Hospital HEM
1950 Circle Of Hope Dr SUITE 2, Salt Lake City 84112
Huntsman Cancer Institute
2000 Circle Of Hope Dr SUITE 2E, Salt Lake City 84112
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Education:
Medical Schools
University of North Carolina At Chapel Hill
Graduated: 1975
University of North Carolina At Chapel Hill
Graduated: 1975
Novel Gene Rno Upregulated In Leukemia Cells By Nitric Oxide And Dmso
US Patent:
2001002, Oct 11, 2001
Filed:
Mar 6, 2001
Appl. No.:
09/799983
Inventors:
Paul Shami - Salt Lake City UT, US
Charles Parker - Salt Lake City UT, US
Charles Parker - Salt Lake City UT, US
International Classification:
C12Q001/68, G01N033/574, C12P021/02, C12N005/06
US Classification:
435/069100, 435/325000, 435/007230, 435/006000
Abstract:
The present invention relates to a novel human gene which has been shown to induce differentiation of cancer cells. The gene is regulated by NO and is named rno. Three isoforms of rno have been isolated and purified, rno-1 (SEQ ID NO: 1), rno-2 (SEQ ID NO: 3), and rno-3 (SEQ ID NO: 5). The rno isoforms each code for a separate amino acid sequence (SEQ ID NOS: 2, 4, & 5 ). The present invention also provides recombinant vectors comprising nucleic acid molecules that code for the rno gene products. In certain embodiments, these recombinant vectors are plasmids. In certain embodiments, these recombinant vectors are prokaryotic or eukaryotic expression vectors. In certain especially preferred embodiments, the nucleic acid coding for the rno gene products are operably linked to a heterologous promoter. The present invention further provides host cells comprising a nucleic acid that codes for the rno gene products (SEQ ID NOS: 2, 4, & 5). The gene products have been shown to induce AML cell differentiation and apoptosis.